From Chemotherapy to Targeted Pills: A New Era in Chronic Myeloid Leukemia and What Asciminib Could Mean for Patients ...

AbbVie Inc. (NYSE:ABBV) is one of the best dividend aristocrat stocks to buy now. On June 19, AbbVie Inc. (NYSE:ABBV) ...

Eli Lilly's cancer drug Jaypirca received a positive opinion from the European Medicines Agency regarding its use in chronic ...

Treatment with so-called BTK inhibitors has improved the prognosis for people with chronic lymphocytic leukemia (CLL). At the same time, these drugs affect the immune system and may cause side effects ...

The chronic phase is the first and most treatable phase of chronic myeloid leukemia. It is characterized by a low percentage of abnormal cells in the blood and bone marrow. With treatment, most people ...

Researchers leading the SWOG S1712 clinical trial have found that adding ruxolitinib to standard tyrosine kinase inhibitor (TKI) treatment for patients with chronic-phase chronic myeloid leukemia ...

Researchers at the University of Eastern Finland and their international collaborators have identified key developmental and molecular differences between the two main subtypes of chronic lymphocytic ...

B-cell chronic lymphocytic leukemia (CLL) occurs when abnormal B cells accumulate in the bone marrow and blood. This crowds out healthy blood cells and weakens the body’s ability to fight infections.

Developments in chronic lymphocytic leukemia (CLL) this year included the first CAR T-cell therapy approval for the chronic blood cancer, potential treatments for Richter transformation, and ...

Korea’s five-year catastrophic illness rule is pushing chronic myeloid leukemia patients to stop lifelong treatment when ...